IDEAYA Biosciences (IDYA) Current Deferred Revenue (2018 - 2025)
IDEAYA Biosciences (IDYA) posted Current Deferred Revenue of $490000.0 for Q3 2025, down 65.95% sequentially from $1.4 million in Q3 2023.
IDEAYA Biosciences (IDYA) Current Deferred Revenue (2018 - 2025) Analysis & Trends
IDEAYA Biosciences has reported Current Deferred Revenue for 6 years, with the latest figure at $490000.0 in Q3 2025.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $490000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $490000.0 (changed N/A YoY) and the FY2022 annual result came in at $8.6 million, down 85.78% from the prior year.
- Current Deferred Revenue fell to $490000.0 in Q3 2025 per IDYA's latest filing, from $1.4 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $62.2 million in Q3 2021 and troughed at $490000.0 in Q3 2025.
- A 4-year average of $23.5 million and a median of $19.9 million in 2021 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue jumped 61.98% in 2022, then slumped 92.14% in 2023.
- Over 4 years, Current Deferred Revenue stood at $60.2 million in 2021, then plunged by 85.78% to $8.6 million in 2022, then plunged by 83.2% to $1.4 million in 2023, then slumped by 65.95% to $490000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $490000.0, $1.4 million, and $2.8 million for Q3 2025, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 490,000.00 |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 2.82 Mn |
| Mar 31, 2023 | 6.26 Mn |
| Dec 31, 2022 | 8.57 Mn |
| Sep 30, 2022 | 17.58 Mn |
| Jun 30, 2022 | 35.85 Mn |
| Mar 31, 2022 | 39.22 Mn |
| Dec 31, 2021 | 60.23 Mn |
| Sep 30, 2021 | 62.18 Mn |
| Jun 30, 2021 | 22.13 Mn |
| Mar 31, 2021 | 25.51 Mn |
| Dec 31, 2020 | 83.77 Mn |
| Sep 30, 2020 | 91.00 Mn |
| Dec 31, 2018 | 299,000.00 |